Oops, you're using an old version of your browser so some of the features on this page may not be displaying properly.

MINIMAL Requirements: Google Chrome 24+Mozilla Firefox 20+Internet Explorer 11Opera 15–18Apple Safari 7SeaMonkey 2.15-2.23

Poster display session

5169 - Reversion of epithelial–mesenchymal transition (EMT) as a mechanism of action of cabazitazel in castration-resistant prostate cancer

Date

11 Sep 2017

Session

Poster display session

Topics

Cytotoxic Therapy;  Translational Research;  Prostate Cancer

Presenters

Natalia Jiménez

Citation

Annals of Oncology (2017) 28 (suppl_5): v573-v594. 10.1093/annonc/mdx390

Authors

N. Jiménez1, M. Marín-Aguilera1, O. Reig1, P.L. Fernández2, S. García-Recio3, M.V. Pereira3, A. Prat1, B. Mellado Gonzalez1

Author affiliations

  • 1 Medical Oncology/translational Genomics And Targeted Therapeutics In Solid Tumors Lab, Hospital Clínic of Barcelona/Institut d'Investigacions Biomèdiques Agust Pi i Sunyer/Fundació Clínic per a la Recerca Biomèdica, 08036 - Barcelona/ES
  • 2 Medical Oncology/translational Genomics And Targeted Therapeutics In Solid Tumors Lab, Hospital Clínic of Barcelona/Institut d'Investigacions Biomèdiques Agust Pi i Sunyer, 08036 - Barcelona/ES
  • 3 Medical Oncology/translational Genomics And Targeted Therapeutics In Solid Tumors Lab, Hospital Clínic of Barcelona/Institut d'Investigacions Biomèdiques Agust Pi i Sunyer/Fundació Clínic per a la Recerca Biomèdica, Barcelona/ES
More

Resources

Abstract 5169

Background

The epithelial to mesenchymal transition (EMT) process is involved in de novo and acquired resistance to hormone-therapy and docetaxel (D) in metastatic castration resistant prostate cancer (mCRPC). Cabazitaxel (CZ) it active after D-progression and prior second-line hormone-therapies. Here we investigated the differences between CZ and D resistance related to the EMT phenotype acquisition and its potential clinical value.

Methods

D and CZ resistant (R) cells lines were derived from parental DU-145 and PC-3. Cell line Molecular characterization was performed using Affymetrix GeneChip Human Gene 2.0 ST microarrays. Gene expression analysis was performed by quantitative real-time PCR in cell lines and in FFPE tumors from mCRPC treated with CZ. Protein levels were measured by Western Blot. Cell migration was assessed using the Cultrex cell migration kit (Trevigen) andcell viability by MTT assay. Gene inhibitory experiments were performed by siRNA transfection.

Results

Microarray data, pathway analysis and EMT gene data in silico validation showed that EMT occurred in both D-R and CZ-R cells, being ZEB1 one of the top deregulated genes. However, we identified 55 EMT genes differentially deregulated between D-R and CZ-R vs parental cells. Among them CDH1, and ESRP1 (lost in D-R but maintained in Cz-R), and AXL (overexpressed in D-R and downregulated in CZ-R). D-R cells presented a more pronounced mesenchymal phenotype (morphology, higher migration and lower proliferation rates, higher expression of EMT markers at mRNA and protein level) than CZ-R. Dose-response experiments showed that CZ induced CDH1 and ESRP1 expression in different cell lines models. ZEB1 inhibition reverted D- resistance, but not CZ-resistance, and restored ESRP1 expression in D-R cells. In 29 CRPC patients treated with CZ, low level of expression of ESRP-1 in tumor correlated with a better PSA-PFS (6.2 vs 2.7 months, P = 0.006; HR: 0.31 P = 0.009) and radiological PFS (7.9 vs 3.3 months, P = 0.047; HR: 0.39 P = 0.055) and the EMT phenotype was not associated to resistance.

Conclusions

The reversion of EMT phenotype, trough induction of CDH1 and ESRP1, may be a novel mechanism of action of CZ, which may explain its activity in patients progressing to prior therapies in CPRC.

Clinical trial identification

Legal entity responsible for the study

Hospital Clínic of Barcelona

Funding

Sanofi-Aventis

Disclosure

All authors have declared no conflicts of interest.

This site uses cookies. Some of these cookies are essential, while others help us improve your experience by providing insights into how the site is being used.

For more detailed information on the cookies we use, please check our Privacy Policy.

Customise settings
  • Necessary cookies enable core functionality. The website cannot function properly without these cookies, and you can only disable them by changing your browser preferences.